All News

Gene Editing

European Commission Grants Approval for CASGEVY™ for Treatment of Sickle Cell Disease and Beta-Thalassemia
13 February 2024
European Commission Grants Approval for CASGEVY™ for Treatment of Sickle Cell Disease and Beta-Thalassemia
The European Commission has granted
Advanced Therapies Week 2024 Opening Plenary: Striving for a Future of Development Whilst Celebrating the Past
8 February 2024
Advanced Therapies Week 2024 Opening Plenary: Striving for a Future of Development Whilst Celebrating the Past
Advanced Therapies Week 2024's Opening
Advanced Therapies Week 2024: Navigating Innovation, Patient-Centricity, and the Regulatory Landscape in Cell and Gene Therapy
7 February 2024
Advanced Therapies Week 2024: Navigating Innovation, Patient-Centricity, and the Regulatory Landscape in Cell and Gene Therapy
In summary, the Superplenary at
Tech Demo: GMP Cyrovial Filling Platform, from 3P Innovation
12 January 2024
Tech Demo: GMP Cyrovial Filling Platform, from 3P Innovation
David Johnson, Sales and Marketing
POPULAR NEWS ITEMS
Image
14 May 2024

Intensified extracellular vesicle production in fixed-bed bioreactors: Discover low-footprint, automated solutions for low-cost extracellular vesicles manufacturing

Image
8 April 2024

Women in Advanced Therapies Global 2024, Virtual Event

Image
25 March 2024

RNA Connect 2025, South Carolina

IN8bio’s INB-200 Demonstrates Remarkable Progression-Free Survival in Newly Diagnosed Glioblastoma Patients
22 November 2023
IN8bio’s INB-200 Demonstrates Remarkable Progression-Free Survival in Newly Diagnosed Glioblastoma Patients
IN8bio, Inc. has presented compelling
First CRISPR/Cas9 Gene-Edited Therapy Authorized by the UK MHRA for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
16 November 2023
First CRISPR/Cas9 Gene-Edited Therapy Authorized by the UK MHRA for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
The First regulatory authorization of
Verve Therapeutics’ VERVE-101 Demonstrates Breakthrough in vivo Base Editing for Familial Hypercholesterolemia
15 November 2023
Verve Therapeutics’ VERVE-101 Demonstrates Breakthrough in vivo Base Editing for Familial Hypercholesterolemia
Verve Therapeutics shows promising reductions
Cellectis and AstraZeneca Forge Innovative Partnership to Pioneer Next-Generation Therapeutics
1 November 2023
Cellectis and AstraZeneca Forge Innovative Partnership to Pioneer Next-Generation Therapeutics
Cellectis announces its collaboration with
Load more News
RECOMENDED TOPICS
Allogeneic
Autologous
CAR-X
Cell Therapy
Cell-Based IO
Gene Editing
Gene Therapy
NKx
Stem Cells
Tissue Engineering
Viral/Non-Viral Vectors
POPULAR NEWS ITEMS
Image

Intensified extracellular vesicle production in fixed-bed bioreactors: Discover low-footprint, automated solutions for low-cost extracellular vesicles manufacturing

Image

Women in Advanced Therapies Global 2024, Virtual Event

Image

RNA Connect 2025, South Carolina